Biomarkers for PTLD diagnosis and therapies

Pediatr Nephrol. 2020 Jul;35(7):1173-1181. doi: 10.1007/s00467-019-04284-w. Epub 2019 Jun 25.


Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of lymphoproliferative disorders and is a serious complication of pediatric transplantation. The majority of PTLD are associated with Epstein Barr virus (EBV) and the characteristic EBV+ B cell lymphomas are the leading post-transplant malignancy in children. EBV+ PTLD remains a formidable issue in pediatric transplantation and is thought to result from impaired immunity to EBV as a result of immunosuppression. However, the key viral and immune factors that determine whether EBV+ PTLD develops remain unknown. Recently, there has been much interest in developing biomarkers in order to improve and achieve more personalized approaches, in the clinical diagnosis, management, and treatment of EBV+ PTLD. Here, we review the status of immune-, viral-, and B cell lymphoma-derived candidates for biomarkers of EBV+ PTLD.

Keywords: Biomarker; EBV; PTLD.

Publication types

  • Review

MeSH terms

  • Biomarkers / blood
  • Child
  • Epstein-Barr Virus Infections / blood
  • Epstein-Barr Virus Infections / complications*
  • Epstein-Barr Virus Infections / immunology
  • Herpesvirus 4, Human / isolation & purification
  • Humans
  • Immunosuppression Therapy / adverse effects
  • Kidney Transplantation / adverse effects*
  • Lymphoma, B-Cell
  • Lymphoproliferative Disorders / diagnosis
  • Lymphoproliferative Disorders / etiology*
  • Lymphoproliferative Disorders / immunology
  • Lymphoproliferative Disorders / therapy
  • Postoperative Complications / etiology
  • Viral Load


  • Biomarkers